CEO webcast: David Solomon on Thalia’s acquisition of Sanmirna and £2.75 million fundraise

In this webcast, CEO David Solomon outlines the strategic rationale for Thalia’s acquisition of Sanmirna and the Company’s concurrent £2.75 million fundraise.

The transaction is a significant milestone for Thalia, moving the Company into clinical stage and adding miRisten, a Phase 1 therapy for acute myeloid leukemia, to its pipeline. The fundraise provides funding through mid-2027, including completion of the miRisten Phase 1 trial, with top-line data expected in H1 2027, and supports progress across Thalia's broader pipeline.

In the webcast, David discusses:

• the strategic importance of the Sanmirna acquisition

• miRisten’s mechanism of action and preclinical results

• the Phase 1 trial design

• the key milestones investors should watch

Next steps for Thalia’s wider pipeline, including bispecific cardiovascular siRNA and Nuvec